SCIENTIFIC AND INFORMATION-ANALYTICAL MAGAZINE

ISSN 1024-6177 (Print), ISSN 2618-9615 (Online)

JOURNAL DESCRIPTION

The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.

Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.

Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.

The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.

Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.

The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.

Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.

The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.

Medical Radiology and Radiation Safety. 2015. Vol. 60. No. 1. P. 5-14

RADIATION BIOLOGY

L.V. Shulenina1, V.F. Mikhailov1, E.V. Ledin2, N.F. Raeva1, G.D. Zasukhina3

Evaluation of P53-Dependent System of Maintaining the Genome Stability by Content of MicroRNA and MRNA in Blood of Cancer Patients

1. A.I. Burnasyan Federal Medical Biophysical Center of FMBA, Moscow, Russia, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. ; 2. Treatment-and-reabilitation Center of Ministry of Health of Russia, Moscow, Russia; 3. Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia

ABSTRACT

Purpose: To explore the content of mature mir125b, mir21, mir34a, mir145, let7a, mir16 and mRNA of P53, MDM2, MDMX genes, modulating activity of p53-dependent system of maintaining the genome stability in blood of cancer patients before and after radiotherapy for evaluation of disease prognosis and identification of the most promising targets for pharmacological correction.

Material and methods: We used the whole blood of patients with prostate cancer, breast cancer, head and neck cancer which was received before and after radiation therapy. The control was the blood of healthy donors. Radiation therapy was carried out on the equipment ROCUS (60Co). The total dose of irradiation was about 70 Gy. The content of the mature microRNA and mRNA was determined using the quantative reverse-transcription real-time PCR with gene-specific primers. Relative expression was calculated according to the method ΔΔCt. Statistical analysis of the results was carried out by the Mann-Whitney and Wilcoxon tests. Data are presented as median and quartiles, normalized to median of control group accepted as 1.

Results: The low expression of MDMX and high content of both mir21 and let7a were found in the blood of prostate cancer patients in comparison with blood of donors. Radiotherapy increased mir34a, but did not influence on another indicators. The breast cancer patients have high level mir145, mir21 and mir 34a before radiotherapy. Expression of MDM2 after radiotherapy declined in blood of these persons. The patients with head and neck cancer revealed significantly high level of mir21, mir145, mir34a and radiotherapy caused an extension of let7a.

Conclusion: The low efficiency of functioning P53- dependent system, maintaining the genome stability is the precondition factor of tumors’ high radioresistance. Inactivation of p53 in cancer cells is due to mutations in the p53 gene, increased activity of the endogenous inhibitors of MDM2, MDMX and balance of mature mir16, 21, 34, 125, 145. It was found the increase of mir145, mir21, mir34a, and let7a content in blood of oncologic patients. It is presumed that the changes of expression these indicators support the information about the effectivity of therapy and for development of p53-dependent-system-drugs.

Key words: radiotherapy, cancer patients, genome stability, p53-dependent system maintaining mir125b, mir21, mir34a, mir145, mir16, let7a, targeted compounds

REFERENCES

  1. Begg A.C., Stewart F.A., Vens C. Strategies to improve radiotherapy with targeted drugs. Nature Reviews. Cancer, 2011. Vol. 11. P. 239-253.
  2. Zheltukhin A.O., Chumakov P.M. Povsednevnye i indutsirovannye funktsii gena R53. Uspekhi biol. khimii. 2010. Vol. 50. P. 447-516.
  3. Maltzman W., Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 1984. Vol. 4. No. 9. P. 1689-1694.
  4. Kastan M.B., Onykwere O., Sidransky D. et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991. Vol. 51. P. 6304-6311.
  5. Graeber T.G., Peterson J.F., Tsai M. et al. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol. Cell. Biol. 1994. Vol. 14. No. 9. P. 6264-6277.
  6. Feki A., Irminger-Finger I. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit. Rev. Oncol. Hematol. 2004. Vol. 52. No. 2. P. 103-116.
  7. Momand J., Jung D., Wilczynski S., Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998. Vol. 26. No. 15. P. 3453-3459.
  8. Shvarts A., Steegenga W.T., Riteco N. et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 1996. Vol. 15. No. 19. P. 5349-5357.
  9. Kolesnikov N.N., Titov S.E., Veryaskina Yu.A. et al. MikroRNK, evolyutsiya i rak. Tsitologiya, 2013. Vol. 55. No. 3. P. 159-164.
  10. Calin G.A., Liu C.G., Sevignani C. et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl. Acad. Sci. USA. 2004. Vol. 101. No. 32. P. 11755-11760.
  11. Zhao J.J., Yang J., Lin J. et al. Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv. Syst. 2009. Vol. 25. No. 1. P. 13-20.
  12. Tenzin W., Lhakhang, Chaudhry M.A. Interactome of radiation-Induced microRNA-predicted target genes. Compar. Func. Genomics. 2012. ID 569731. P. 12.
  13. Halimi M., Mohsen Asghari S., Sariri R. et al. Cellular response to ionizing radiation: A microRNA story. IJMCM. 2012. Vol. 11. No. 4. P. 178-184.
  14. Valadi H., Ekstrom K., Bossios A. et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell. Biol. 2007. Vol. 9. No. 6. P. 654-659.
  15. Olivier M., Eeles R., Hollstein M. et al. The IARCTP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 2002. Vol. 19. No. 6. P. 607-614.
  16. Ventura A., Kirsch D.G., McLaughlin M.E. et al. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007. Vol. 445. P. 661-665.
  17. Suad O., Rozenberg H., Brosh R. et al. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. J. Mol. Biol. 2009. Vol. 385. No. 1. P. 249-265.
  18. Mandinova A., Lee S.W. The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and Promise. Sci. Transl. Med. 2011. Vol. 3. No. 64. P. 1-13.
  19. Secchiero P., Bosco R., Celeghini C., Zauli G. Recent advances in the therapeutic perspectives of Nutlin-3. Curr. Pharm. Des. 2011. Vol. 17. No. 6. P. 569-577.
  20. Reed D., Shen Y., Shelat A.A. et al. Identification and characterization of the first small molecule inhibitor of MDMX. J. Biol. Chem. 2010. Vol. 285. P. 10786-10796.
  21. Sorenson G.D., Pribish D.M., Valone F.H. et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol. Biomark. Prev. 1994. Vol. 3. No. 1. P. 67-71.
  22. Wagner J. Free DNA — new potential analyte in clinical laboratory diagnostics? Biochem. Med. (Zagreb), 2012. Vol. 22. No. 1. P. 24-38.
  23. Ziegler A., Zangemeister-Wittke U., Stahel R.A. Circulating DNA: a new diagnostic gold mine? Cancer Treat. Rev. 2002. Vol. 28. No. 5. P. 255-271.
  24. Friel A.M., Corcoran C., Crown O’Driscoll L. Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer. Breast Cancer Res. Treat. 2010. Vol. 123. No. 3. P. 613-625.
  25. Gormally E., Vineis P., Matullo G. et al. TP53and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence. A Prospective Study.Cancer Res. 2006. Vol. 66. No. 13. P. 6871-6876.
  26. Mikhailov V.F., Ushenkova L.N., Shagirova Zh.M., Shulenina L.V. Issledovanie mutatsii v onkogenakh i genakh supressorakh opukholei kak podkhod k izyskaniyu sposobov individual'nogo prognoza otdalennykh posledstvii oblucheniya. Radiats. biologiya. Radioekologiya. 2010. vol. 50. No. 2. P. 128-133.
  27. Dongsheng P., Zhang Y., Zheng J. Regulation of p53: a collaboration between Mdm2 and MdmX. Oncotarget. 2012. Vol. 3. No. 3. P. 228-235.
  28. Manfredi J.J. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes. Dev. 2010. Vol. 24. No. 15. P. 1580-1589.
  29. Pan B.T., Johnstone R.M. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 1983. Vol. 33. No. 3. P. 967-978.
  30. Raposo G., Nijman H.W., Stoorvogel W. et al. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 1996. Vol. 183. No. 3. P. 1161-1172.
  31. Blanchard N., Lankar D., Faure F. et al. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. J. Immunol. 2002. Vol. 168. No. 7. P. 3235-3241.
  32. Van Niel G., Raposo G., Candalh C. et al. Intestinal epithelial cells secrete exosome-like vesicles. Gastroenterology. 2001. Vol. 121. No. 2. P. 337-349.
  33. Mears R., Craven R.A., Hanrahan S. et al. Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. Proteomics. 2004. Vol. 4. No. 12. P. 4019-4031.
  34. Vickers K.C., Remaley A.T. Lipid-based carriers of microRNAs and intercellular communication. Curr. Opin. Lipidol. 2012. Vol. 23. No. 2. P. 91-97.
  35. Arroyo J.D., Chevillet J.R., Kroh E.M. et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. USA. 2011. Vol. 108. No. 12. P. 5003-5008.
  36. Li Y., Elashoff D., Oh M. et al. Serum circulating human mRNA profiling and Its utility for oral cancer detection. J. Clin. Oncol. 2006. Vol. 24. No. 11. P. 1754-1776.
  37. Wakuma T., Lozano G. MDM2, an introduction. Mol. Cancer Res. 2003. Vol. 1. No. 14. P. 993-1000.
  38. Lukas J., Gao D.Q., Keshmeshian M. et al. Alternative and aberrant messenger RNA splicing of the MDM2 oncogene in invasive breast cancer. Cancer Res. 2001. Vol. 61. No. 7. P. 3212-3219.
  39. Owrangi B., Habibagahi M., Hosseini A. et al. MDM2, E-cadherin, Survivin and Her2 mRNA Status in Peripheral Blood of Patients with Breast Cancer. Middle East J. Cancer. 2013. Vol. 4. No. 1. P. 7-14.
  40. Zhang Z., Li M., Wang H. et al. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. PNAS, 2003. Vol. 100. No. 20. P. 11636-11641.
  41. Wang H., Yan C. A Small-Molecule p53 activator induces apoptosis through Inhibiting MDMX expression in breast cancer cells. Neoplasia, 2011. Vol. 13. No. 7. P. 611-619.
  42. Yaman A.F., Kovancilar M., Dizdar Y. et al. Investigation of miR-21, miR-141 and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol. 2011. Vol. 32. No. 3. P. 583-588.
  43. Roth C., Rack B., Muller V. et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 2010. Vol. 12. No. 6. P. 1-8.
  44. Komatsu S., Ichikawa D., Takeshita H. et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Brit. J. Cancer. 2011. Vol. 105. No. 1. P. 104-111.
  45. Takamizawa J., Konishi H., Yanagisawa K. et al. Reduced expression of the let-7 micrornas in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004. Vol. 64. No. 11. P. 3753-3756.
  46. Wing Pui Tsang, Tim Tak Kwok. Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis, 2008. Vol. 13. No. 10. P. 1215-1222.
  47. Feng Y., Zhu J., Ou C. et al. MicroRNA-145 inhibits tumour growth and metastasis in colorectal cancer by targeting fascin-1. Brit. J. Cancer. 2014. Vol. 110. P. 2300-2309.
  48. Rocca G., Shi Bin, Audia A. et al. Regulation of microRNA-145 by growth arrest and differentiation. Exper. Cell Res. 2011. Vol. 317. No. 4. P. 488-495.
  49. Seok-Jun Kim, Ji-Sun Oh, Ji-Young Shin et al. Development of microRNA-145 for therapeutic application in breast cancer. J. Controlled Release. 2011. Vol. 155. No. 3. P. 427-434.
  50. Xin Yan, Hongwei Liang, Ting Deng et al. The identification of novel targets of miR-16 and characterization of their biological functions in cancer cells. Mol. Cancer. 2013. Vol. 12. No. 1. P. 1-11.
  51. He L., He X., Lim L.P.,et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007. Vol. 447. No. 7148. P. 1030-1038.
  52. Rokavec M., Li H., Jiang L., Hermeking H. The p53/miR-34 axis in development and disease. J. Mol. Cell. Biol. 2014. Vol. 6. No. 3. P. 214-230.
  53. Bader A.G. miR-34 — a microRNA replacement therapy is headed to the clinic. Front Genet. 2012. Vol. 3. No. 120. P. 1-9.
  54. Dutta K.K., Zhong Y., Liu Y. et al. Association of microRNA-34aoverexpression with proliferation is cell type-dependent. Cancer Sci. 2007. Vol. 98. No. 12. P. 1845-1852.
  55. Sun Y.-, Lin K.-Y., Chen Y.-Q. Diverse functions of miR-125 family in different cell contexts. J. Hematol. & Oncol. 2013. Vol. 6. No. 6. P. 1-8.
  56. Tang , Zhang R., He Y. et al. MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7 and MDA-MB-231 breast cancer cells. PLoS One. 2012. Vol. 7. No. 5. P. e35435.
  57. Oh J.S., Kim J.J., Byun J.Y., Kim I.A. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int. J. Radiat. Oncol. Biol. Phys. 2010. Vol. 76. No. 1. P. 5-8.
  58. Zhu Y., Yu X., Fu H. et al. MicroRNA-21 is involved in ionizing radiation-promoted liver carcinogenesis. Int. J. Clin. Exp. Med. 2010. Vol. 3. No. 3. P. 211-222.

For citation: Shulenina LV, Mikhailov VF, Ledin EV, Raeva NF, Zasukhina GD. Evaluation of P53-Dependent System of Maintaining the Genome Stability by Content of MicroRNA and MRNA in Blood of Cancer Patients. Medical Radiology and Radiation Safety. 2015;60(1):5-14. Russian.

PDF (RUS) Full-text article (in Russian)

Contact Information

 

46, Zhivopisnaya st., 123098, Moscow, Russia Phone: +7 (499) 190-95-51. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal location

Attendance

2941330
Today
Yesterday
This week
Last week
This month
Last month
For all time
2456
2306
18568
33458
39626
113593
2941330
Forecast today
4488

Your IP:216.73.216.100
Visitor Counter

© Журнал "Медицинская радиология и радиационная безопасность" 2020г.

Яндекс.Метрика

Наверх